anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Microsporidia are unfriendly microorganisms, and their infections cause considerable damage to economically or environmentally important insects like silkworms and honeybees. Thus, the identification of measures to improve host resistance to microsporidia infections is critically needed. Here, an overexpressed miR-6498-5p transgenic silkworm line was constructed. Importantly, the survival rates and median lethal doses of the transgenic line were clearly higher after infection with Nosema bombycis. H&E staining and RT-qPCR analyses revealed an inhibitory effect on the proliferation of N. bombycis in the transgenic larvae. Metabolomics analysis further revealed the presence of 56 differential metabolites between the two lines. KEGG analysis of these 56 metabolites found that they were involved in various amino acid and vitamin metabolism pathways. Notably, VB6 metabolism was enriched among the metabolites, and the pathway was well known for its involvement in the synthesis, interconversion, and degradation of amino acids. These suggest that miR-6498-5p modifies parasitic environments to inhibit the proliferation of N. bombycis by affecting the host amino acid metabolism. These results demonstrate the potential of microRNAs as biomolecules that can promote resistance to microsporidia and provide new insights and a new approach to generate microsporidia-resistant biological materials.IMPORTANCEMicrosporidia have an extremely wide host range and are capable of infecting a wide variety of insects and vertebrates, including humans, and their lethality to multiple species often poses significant environmental management challenge. Here, we successfully constructed a microsporidium-resistant line in the silkworm, based on the overexpression of miR-6498-5p. Our results strongly support the hypothesis that miR-6498-5p efficiently suppresses the proliferation of Nosema bombycis by regulating the host VB6 metabolism, a key pathway for enzymes involved in amino acid transport and protein metabolism. Our study provides new insights for understanding host anti-pathogen defenses toward microsporidia.
In-patients from cardiology department of The First Affiliated Hospital with Nanjing Medical University will be screened using inclusion/exclusion criteria for patients. Among the patients who meet the criteria and willing to give an informed consent, 30 patients with youngest CAD-diagnosed-age will be enrolled as cases.
The application discloses an application of a honeysuckle extract in preparation of an ATP citrate lyase inhibitor 50 The value was 2.65. + -. 0.83. mu.g/mL, and the result was significantThe plant extract has the treatment effect on hyperlipidemia, atherosclerosis, fatty liver, type II diabetes, cancer and other diseases mediated by ACL, so that the plant extract has great potential application in the field of pharmacy. The honeysuckle extract of the present application can be prepared by methods well known to those skilled in the art. For example, honeysuckle flower is used as raw material, and solvent extraction and chromatography can be adopted to prepare concentrated honeysuckle flower extract. Based on the application, the application also provides an ATP citrate lyase inhibitor, which takes honeysuckle extract as an active ingredient, and the honeysuckle extract is independently used or is prepared into a medicament with a pharmaceutically acceptable carrier or excipient.
INTRODUCTION: Tanzania has one of the highest burdens of perinatal mortality, with a higher risk among urban versus rural women. To understand the characteristics of perinatal mortality in urban health facilities, study objectives were: I. To assess the incidence of perinatal deaths in public health facilities in Dar es Salaam and classify these into a) pre-facility stillbirths (absence of fetal heart tones on admission to the study health facilities) and b) intra-facility perinatal deaths before discharge; and II. To identify determinants of perinatal deaths by comparing each of the two groups of perinatal deaths with healthy newborns.
METHODS: This was a retrospective cohort study among women who gave birth in five urban, public health facilities in Dar es Salaam. I. Incidence of perinatal death in the year 2020 was calculated based on routinely collected health facility records and the Perinatal Problem Identification Database. II. An embedded case-control study was conducted within a sub-population of singletons with birthweight ≥ 2000 g (excluding newborns with congenital malformations); pre-facility stillbirths and intra-facility perinatal deaths were compared with 'healthy newborns' (Apgar score ≥ 8 at one and ≥ 9 at five minutes and discharged home alive). Descriptive and logistic regression analyses were performed to explore the determinants of deaths.
RESULTS: A total of 37,787 births were recorded in 2020. The pre-discharge perinatal death rate was 38.3 per 1,000 total births: a stillbirth rate of 27.7 per 1,000 total births and an intra-facility neonatal death rate of 10.9 per 1,000 live births. Pre-facility stillbirths accounted for 88.4% of the stillbirths. The case-control study included 2,224 women (452 pre-facility stillbirths; 287 intra-facility perinatal deaths and 1,485 controls), 99% of whom attended antenatal clinic (75% with more than three visits). Pre-facility stillbirths were associated with low birth weight (cOR 4.40; (95% CI: 3.13-6.18) and with maternal hypertension (cOR 4.72; 95% CI: 3.30-6.76). Intra-facility perinatal deaths were associated with breech presentation (aOR 40.3; 95% CI: 8.75-185.61), complications in the second stage (aOR 20.04; 95% CI: 12.02-33.41), low birth weight (aOR 5.57; 95% CI: 2.62-11.84), cervical dilation crossing the partograph's action line (aOR 4.16; 95% CI:2.29-7.56), and hypertension during intrapartum care (aOR 2.9; 95% CI 1.03-8.14), among other factors.  CONCLUSION: The perinatal death rate in the five urban hospitals was linked to gaps in the quality of antenatal and intrapartum care, in the study health facilities and in lower-level referral clinics. Urgent action is required to implement context-specific interventions and conduct implementation research to strengthen the urban referral system across the entire continuum of care from pregnancy onset to postpartum. The role of hypertensive disorders in pregnancy as a crucial determinant of perinatal deaths emphasizes the complexities of maternal-perinatal health within urban settings.
BACKGROUND: Cancer of unknown primary (CUP) is defined as a primary metastatic malignancy, in which the primary tumor remains elusive in spite of a comprehensive diagnostic workup. The frequency and prognostic value of circulating tumor cells (CTCs), which are considered to be the source of metastasis, has not yet been systematically evaluated in CUP.
METHODS: A total of 110 patients with a confirmed diagnosis of CUP according to the European Society for Medical Oncology (ESMO) guidelines, who presented to our clinic between July 2021 and May 2023, provided blood samples for CTC quantification using CellSearch methodology. CTC counts were correlated with demographic, clinical, and molecular data generated by comprehensive genomic profiling of tumor tissue.
RESULTS: CTCs were detected in 26% of all patients at initial presentation to our department. The highest CTC frequency was observed among patients with unfavorable CUP (35.5%), while patients with single-site/oligometastatic CUP harbored the lowest CTC frequency (11.4%). No statistically significant association between CTC positivity and the number of affected organs (P = 0.478) or disease burden (P = 0.120) was found. High CTC levels (≥5 CTCs/7.5 mL; 12/95 analyzed patients) predicted for adverse overall survival compared to negative or low CTC counts (6-months overall survival rate 90% vs 32%, log-rank P < 0.001; HR 5.43; 95% CI 2.23-13.2). CTC dynamics were also prognostic for overall survival by landmark analysis (log-rank P < 0.001, HR 10.2, 95% CI 1.95-52.9).
CONCLUSIONS: CTC frequency is a strong, independent predictor of survival in patients with CUP. CTC quantification provides a useful prognostic tool in the management of these patients.
As a result of the recent advances in the treatment of breast cancer carried out by dedicated researchers and made possible through breast cancer research, its mortality has been gradually declining. Naturally, the quality of survivorship has taken an important role in the last 3 decades. Unfortunately, for most women with breast cancer, their concerns about survival are followed closely with concerns about body image, sexuality, self-esteem and social life. Mastectomy, a mainstay in the treatment of breast cancer, is the primary cause of these latter concerns. The investigators are therefore charged with looking at the disease and the respective treatment of breast cancer holistically. Providing a comprehensive management of breast cancer today requires attention to both oncologic principles and to the patient's quality of life. A large part of the patient's quality of life comes from improved reconstructive and aesthetic outcomes following mastectomy. In short, breast reconstruction after mastectomy for cancer aims to improve body image and quality of life by reducing the negative psychological impact of the deformity. Multiple techniques exist to accomplish this goal. They include breast implants, autologous tissues, or occasionally, a combination thereof. Although the ultimate goal is to recreate an aesthetically pleasing breast that attempts to match the missing one, the decision to use a particular technique is multi-factorial. It may be influenced by the surgeon's skills, the patient's preferences, inherent contraindications with a patient, or the resources available in a particular setting. Breast reconstructions can be costly to patients (indirect costs), third party payers and society, especially as new technologies are introduced in clinical practice. In the last 2 decades third party payers and governments in different jurisdictions have been advocating for production of evidence that shows "value for money" germane to these different procedures.Presently, the two most common approaches to breast reconstruction are the AAT method and the TE/I method. These two approaches to breast reconstruction have yet to be submitted to an economic evaluation using state-of-the-art cost-effectiveness analysis.
PURPOSE:To obtain the titled agent effective in suppressing the increase of serum cholesterol level caused by intake of food, by culturing lactic bacteria belonging to Lactobacillus genus or Bifidobacterium genus and using the obtained cultured product or microbial cell as an active component. CONSTITUTION:A lactic bacterial strain belonging to Lactobacillus genus [e.g. Lactobacillus acidophilus SBT-2056 (FERM P-8744)] or Bifidobacterium genus [Bifidobacterium longum SBT-2933R (FERM P-8743)] is cultured and the obtained cultured product or microbial cell is used as an active component of the objective agent. The cultured product or bacterial cell suppresses the alimentary cholesterol increase caused by the intake of cholesterol-rich food (e.g. yolk, butter, etc.). The suppressing agent may be administered by adding about 2-5wt% freeze-dried cell, etc., to a cholesterol-rich food and taking the agent simultaneous with the food or before or after meals.
This study aims to explore the influence of coinfection with HCV and HIV on hepatic fibrosis. A coculture system was set up to actively replicate both viruses, incorporating CD4 T lymphocytes (Jurkat), hepatic stellate cells (LX-2), and hepatocytes (Huh7.5). LX-2 cells' susceptibility to HIV infection was assessed through measurements of HIV receptor expression, exposure to cell-free virus, and cell-to-cell contact with HIV-infected Jurkat cells. The study evaluated profibrotic parameters, including programed cell death, ROS imbalance, cytokines (IL-6, TGF-β, and TNF-α), and extracellular matrix components (collagen, α-SMA, and MMP-9). The impact of HCV infection on LX-2/HIV-Jurkat was examined using soluble factors released from HCV-infected hepatocytes. Despite LX-2 cells being nonsusceptible to direct HIV infection, bystander effects were observed, leading to increased oxidative stress and dysregulated profibrotic cytokine release. Coculture with HIV-infected Jurkat cells intensified hepatic fibrosis, redox imbalance, expression of profibrotic cytokines, and extracellular matrix production. Conversely, HCV-infected Huh7.5 cells exhibited elevated profibrotic gene transcriptions but without measurable effects on the LX-2/HIV-Jurkat coculture. This study highlights how HIV-infected lymphocytes worsen hepatic fibrosis during HCV/HIV coinfection. They increase oxidative stress, profibrotic cytokine levels, and extracellular matrix production in hepatic stellate cells through direct contact and soluble factors. These insights offer valuable potential therapies for coinfected individuals.
All participants will be trialing the 5 devices and reporting their thoughts on comfort, and perception of symptoms of mechanical nasal obstruction by way of survey completion. The devices include 4 commercially available nasal dilators: Breathe Right, Max Air, Sleep Right, Nozovent, and the study team's investigational device dubbed the Schnozzle.
PURPOSE:To speedily read out the past picture of an old patient from a recording medium by recording all the pictures including the past pictures of the old patients to one recording medium. CONSTITUTION:For reading the picture of the old patient, the past pictures are once collected to a picture display device 22 and read. At such a time, the collected past pictures are put together with a picture photographed on a day and they are written into an erasable recording medium 22b again. Therefore, all the pictures of one patient are collected to one erasable recording medium 22b. Namely, when the data of the old patient is preserved, the past picture read in advance of the patient and the picture inspected on that day are totally recorded to one erasable recording medium 22b. Thus, when the picture is read out again, all the pictures of one patient can be read from one erasable recording medium 22b by one time access operation.
Participants will be treated with i.v. 15×10\^6U/m\^2/d IFN-a2b on days 1 to 5 each week for 4 weeks, followed by s.c. 9×10\^6U IFN- a2b three times per week for 48 weeks.
PTSD is associated with high rates of mortality from suicide and health complications, high healthcare costs, and diminished health and quality of life. Many military veterans have PTSD due to combat, and many veterans continue to carry the symptoms of PTSD into late life. The percentage of older veterans is expected to increase substantially in coming years (especially as Vietnam-era veterans become older adults). The psychosocial intervention with the most rigorous empirical support for treating PTSD in the general population is a cognitive-behavioral treatment known as exposure therapy (which involves helping patients face feared memories and situations), yet there have been no controlled studies of any psychosocial interventions for PTSD in samples of older adults. Some have argued that older adults will not respond well to exposure because of their cognitive limitations. However, several empirical studies have shown exposure therapy to be safe and effective with older adults with anxiety disorders other than PTSD.

The current project represents the first randomized clinical trial of psychotherapy for older veterans with posttraumatic stress disorder (PTSD). It will compare relaxation training (RT) to prolonged exposure therapy (PE). The project will also examine whether cognitive impairment influences psychotherapy outcome. The five-year Research Plan is divided into three phases. Phase 1 (Year 1) involves the development of procedures for assessment and preparation for the clinical trial. Phase 2 (Years 2-4) will entail the first randomized clinical trial of psychosocial treatments for PTSD in late life. One hundred veterans aged 60 years or older, with chronic PTSD, will be recruited from the San Diego VA PTSD Clinical Team and randomly assigned to 12 sessions of PE or 12 sessions of RT. Phase 3 (Year 5) will be comprised of final data collection, scoring and interpretation of all neuropsychological tests, data cleaning and analysis, and writing for publication of results. Primary hypotheses: (1) Subjects in the PE condition will have significantly less severe PTSD symptoms, depressive symptoms, and functional impairment than subjects in the RT condition at posttest; (2) Executive functioning will modify the response to both treatments, such that those with impaired executive functioning will demonstrate a smaller reduction in PTSD symptoms (representing less clinically significant change).
Participants randomized to this arm receive the MAPSS-MS intervention. The MAPSS-MS is an an 8 week computer assisted cognitive rehabilitation intervention. The group based component of the intervention emphasizes use of compensatory cognitive strategies as well as lifestyle modifications to enhance cognition. Participants also complete home computer training (minimum 3 times per week for 45 minutes) using a special suite of games designed by Lumosity.
A phosphorous compound such as STMP is used as a cross-linking agent while making a starch nanoparticle with a bisphosphonate drug in an emulsion process. Negative charge of the nanoparticle is optionally reduced or reversed by adding cations and/or cationizing the starch optionally while forming the nanoparticles. Anionic active agents, such as a bisphosphonate, are optionally incorporated into the nanoparticle during the formation process. For example, a bisphosphonate salt can be added, which promotes the crosslinking reaction while also providing bisphosphonate in the nanoparticle. The retention of both calcium and bisphosphonate in the nanoparticle is improved when both salts are used. Alternatively, the nanoparticle may be used without added calcium. The nanoparticles may be useful for the treatment of osteoporosis or other skeletal disorders or cancer.
The invention comprises aminophenylmercapto-pyrimidines of the formula <FORM:0879194/IV (b)/1> and salts thereof with physiologically tolerable acids, wherein Ph represents a phenylene radical optionally bearing halogen or alkoxy substituents and R is an amino or dialkylaminoalkylamino group, with the proviso that R in the para position of an unsubstituted phenylene radical must be a dialkylaminoalkylamino group.  The compounds are prepared by reacting a 4-halopyridine with a benzene-thiol or a metal salt thereof, bearing a substituent R or a group convertible thereto by reduction or hydrolysis, or conversely reacting a 4-mercapto-pyridine or a metal salt thereof with a substituted halo-benzene and subsequently, if necessary, converting a substituent on the benzene ring into the group R and/or converting a product wherein R is an amino group into one wherein R is a dialkylaminoalkylamino group, and if desired converting a free base obtained into a salt or a salt into the free base.  The conversion of an amino group R into a dialkylaminoalkyl group is suitably effected by treating the amino compound with an arylsulphonylhalide to give a sulphamoyl derivative, e.g. 4-(ptoluenesulphonylaminophenylmercapto)-pyridine and reacting with a dialkylaminoalkyl halide in the presence of a condensing agent. Specified products are the m-amino, o-amino, o-amino-p-methoxy, p-amino-o-chloro-and p-b -diethylaminoethyl-, 4-phenylmercapto-pyridines.  Nitrophenylmercapto-pyridines corresponding to the above specified amino products are obtained as intermediates in the examples.ALSO:Pharmaceutical preparations having tranquilizing activity comprise aminophenylmercapto-pyridines of the formula <FORM:0879194/VI/1> in which Ph represents a phenylene, alkoxyphenylene or halophenylene radical and R is an amino or dialkylaminoalkylamino group, with the proviso that when Ph is an unsubstituted phenyl radical R may not be a free para-amino group, or physiologically tolerable salts of these compounds with inorganic and organic acids (see Group IV (b)), in admixture or conjunction with a pharmaceutical carrier suitable for enteral, parenteral or topical administration.  The preparations suitably take the form of tablets, dragees, solutions, suspensions or emulsions and may contain other therapeutically valuable substances.
The present invention relates to the identification and purification of a herpes protease and a nucleic acid segment coding for two proteins. The first protein is the herpes protease which is able to cleave itself and also cleave the second protein. This protease is required for the assembly of the herpes virus capsid, therefore is essential for replication. The second protein has previously been designated as the family of proteins in viral infected cells, ICP35. The protease and its substrates are encoded by overlapping nucleic acid segments. This invention also relates to a promoter sequence for the second protein. Methods are presented of producing a viral protease, screening a protease inhibitor which may be used in a drug designed for the treatment of herpes disease, methods for treating herpes and other viral infections wherein the virus employs a protease substantially similar to the herpes protease, for capsid production. Methods for detecting herpes infections and other viral infections are also disclosed.
Metastases arise from subsets of cancer cells that disseminate from the primary tumour1,2. The ability of cancer cells to thrive in a new tissue site is influenced by genetic and epigenetic changes that are important for disease initiation and progression, but these factors alone do not predict if and where cancers metastasize3,4. Specific cancer types metastasize to consistent subsets of tissues, suggesting that primary tumour-associated factors influence where cancers can grow. We find primary and metastatic pancreatic tumours have metabolic similarities and that the tumour-initiating capacity and proliferation of both primary-derived and metastasis-derived cells is favoured in the primary site relative to the metastatic site. Moreover, propagating cells as tumours in the lung or the liver does not enhance their relative ability to form large tumours in those sites, change their preference to grow in the primary site, nor stably alter aspects of their metabolism relative to primary tumours. Primary liver and lung cancer cells also exhibit a preference to grow in their primary site relative to metastatic sites. These data suggest cancer tissue of origin influences both primary and metastatic tumour metabolism and may impact where cancer cells can metastasize.
PURPOSE: To obtain the subject enhancer, containing an interleukin 6 antagonist and capable of enhancing antitumor actions of an antitumor agent, reducing the required dose of the antitumor agent and further raising the sensitivity of the antitumor agent even to tumors resistant to treatment. CONSTITUTION: This enhancer contains an interleukin 6 (IL-6) antagonist. An IL-6R antibody such as PM-1 antibody is preferred as the IL-6 antagonist. The antibody is preferably obtained by carrying out a well-known method, etc., for using IL-6 as a sensitization antigen, immunizing an animal therewith, then fusing an immunized cell to a cell of a myeloma and subsequently producing the monoclonal antibody in a cell, screened from the fused cell and capable of producing the monoclonal antibody. Furthermore, the IL-6R which is the sensitization antigen is preferably derived from a human. Mitomycin C or a platinum compound such as cisplatin or carboplatin is preferred as an antitumor agent used in combination with the enhancer.